600664 Stock Overview
Engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 600664 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Harbin Pharmaceutical Group Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥3.78 |
| 52 Week High | CN¥4.97 |
| 52 Week Low | CN¥2.54 |
| Beta | 0.17 |
| 1 Month Change | -14.29% |
| 3 Month Change | -6.67% |
| 1 Year Change | 35.00% |
| 3 Year Change | 18.13% |
| 5 Year Change | -19.75% |
| Change since IPO | 507.29% |
Recent News & Updates
Recent updates
Is Harbin Pharmaceutical Group (SHSE:600664) Using Too Much Debt?
Dec 31
Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings
Jun 25We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease
May 25Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
Apr 17Shareholder Returns
| 600664 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.9% | 0.8% | 1.9% |
| 1Y | 35.0% | 3.4% | 17.4% |
Return vs Industry: 600664 exceeded the CN Pharmaceuticals industry which returned 4.5% over the past year.
Return vs Market: 600664 exceeded the CN Market which returned 18.1% over the past year.
Price Volatility
| 600664 volatility | |
|---|---|
| 600664 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 600664 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600664's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 9,853 | n/a | www.hayao.com |
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, recombinant human erythropoietin injections, ibuprofen granules, iron vitamin B12 oral solutions, ceftriaxone sodium injections, pediatric acetaminophen granules, Jiananxi Vitapak nutrition packages, lacidipine tablets, roxatidine acetate hydrochloride for injections, and penicillin and cephalosporin antibiotic preparations.
Harbin Pharmaceutical Group Co., Ltd. Fundamentals Summary
| 600664 fundamental statistics | |
|---|---|
| Market cap | CN¥9.52b |
| Earnings (TTM) | CN¥613.05m |
| Revenue (TTM) | CN¥16.22b |
15.5x
P/E Ratio0.6x
P/S RatioIs 600664 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600664 income statement (TTM) | |
|---|---|
| Revenue | CN¥16.22b |
| Cost of Revenue | CN¥11.65b |
| Gross Profit | CN¥4.57b |
| Other Expenses | CN¥3.95b |
| Earnings | CN¥613.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 26, 2025
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 28.16% |
| Net Profit Margin | 3.78% |
| Debt/Equity Ratio | 30.2% |
How did 600664 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 07:40 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Harbin Pharmaceutical Group Co., Ltd. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xing Qiu Lin | AJ Securities Co., Ltd |
| Ling Bo Tu | China Minzu Securities |
| Wayne He | China Stock Investment Research Co. Ltd. (GZ500..com) |